MES reprogramming is equally a challenge to GBM alkylator chemotherapy where transcription factors such as the forkhead box protein O1 (FOXO1) drive MES resistance reprogramming in GBM to alkylators [103]. Here, FOXO1 is linked to glioblastoma.